Pelthos Therapeutics Inc. (PTHS) stock
Close on Nov 11, 2026Market cap $35.95MP/E –Yield –
Pelthos Therapeutics Inc. reported revenue of $51.29M for the twelve months to Sep 30, 2026. Free cash flow was -$32.56M. At the latest close the market valued the company at $35.95M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $35.95M
- P/E ratio
- –
- Price to sales
- 0.83
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $51.29M
- Net income
- -$78.05M
- EPS, diluted
- -$23.07
- Free cash flow
- -$32.56M
- Book value per share
- -$1.60
- Diluted shares
- 4M
Trading
- Next earnings
- Nov 12, 2026 (estimated, before the open)
- Previous close
- $8.90
- Open
- $8.72
- Day's range
- $8.72 – $9.61
- Volume
- 20,619
- Average volume (20 days)
- 66,431
- Beta (5 years)
- 1.71
- 52-week range
- $8.72 – $37.40
- RSI (14 days)
- 29.0
- Volatility (1 year)
- 91.7%
- Relative volume
- 0.34×
- WACC
- 13.4%
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | PTHS | S&P 500 | Difference | PTHS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -54.2% | -2.4% | −51.8 pts | ||
| 3 months | -67.2% | -1.2% | −66.1 pts | ||
| Year to date | -69.7% | +12.3% | −82.0 pts | ||
| 1 year | -71.5% | +12.4% | −84.0 pts | ||
| 3 years | +4595.0% | +78.8% | +4516.2 pts | +260.8% | +21.4% |
| 5 years | +4595.0% | +75.2% | +4519.8 pts | +115.9% | +11.9% |
| 10 years | +3030.0% | +311.1% | +2718.9 pts | +41.1% | +15.2% |
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Pelthos Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Results
- Update
- Update
- Results
About Pelthos Therapeutics
Biological Products, (No Diagnostic Substances)
Pelthos Therapeutics Inc. is a biopharmaceutical company that commercializes treatments for dermatological conditions and pain management. The company maintains a portfolio of three therapies approved by the FDA: ZELSUVMI, a topical gel for molluscum contagiosum; XEPI, an antimicrobial cream for impetigo; and XEGLYZE, a pediculicide for head lice. In addition, the firm develops clinical-stage, non-opioid pain candidates targeting sodium channels. Its customer base includes adult and pediatric patients with skin conditions, as well as prescribing healthcare professionals such as pediatricians and dermatologists. The company distributes its commercial therapies through retail chains, mail-order services, and digital pharmacies.
Company profile, executives and historyPelthos Therapeutics stock: common questions
What is Pelthos Therapeutics's stock price?
PTHS closed at $9.39 on Nov 11, 2026, up 5.51% on the day. Over the past 52 weeks it traded between $8.72 and $37.40.
What is Pelthos Therapeutics's market cap?
Pelthos Therapeutics was worth $35.95M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is PTHS's P/E ratio?
Pelthos Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$23.07), so it has no meaningful P/E ratio.
How much revenue does Pelthos Therapeutics make?
Pelthos Therapeutics reported revenue of $51.29M for the twelve months to Sep 30, 2026.
Does Pelthos Therapeutics pay a dividend?
No. Pelthos Therapeutics has not paid a cash dividend over the last twelve months.
When does Pelthos Therapeutics report earnings next?
Pelthos Therapeutics is expected to report Q3 FY2026 results on Nov 12, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has PTHS stock performed over the past year?
Including dividends, PTHS returned -71.5% over the past year, against +12.4% for the S&P 500.
Who are Pelthos Therapeutics's competitors?
Companies most similar to Pelthos Therapeutics by business, industry and size include SCLX, PLX, CHRS, BFRI, IVVD.
See a number that looks wrong?